What did @drdrewtimmermans actually say?
The claim is simple: "300 mic sub-Q" once daily is the standard BPC-157 dose for chronic pain, with occasional adjustments like splitting or doubling. That's the whole transcript. No mechanism explanation, no patient selection criteria, no mention of what conditions this applies to or why sub-cutaneous injection was chosen over oral or intranasal routes.
To be fair, this appears to be a short-form clip pulled from a longer discussion. But what was said still carries weight at 86K views. People will take "300 micrograms sub-Q daily" and run with it, and that's worth examining carefully.
Does the science back this up?
Not cleanly, because there is no FDA-approved BPC-157 product, which means there are no Phase III clinical trials establishing any human dosing standard. Everything circulating in clinical practice is extrapolated from animal models, and that gap matters more than most TikTok peptide content acknowledges.
The animal literature is genuinely interesting. Studies like Sikiric et al. (2018, Current Pharmaceutical Design) documented significant tendon and soft tissue healing effects in rodents at doses roughly equivalent to 1-10 mcg/kg body weight. A 70kg human would land somewhere in the 70-700 mcg range from that extrapolation, so 300 mcg is not an unreasonable number to land on mathematically. But rodent-to-human pharmacokinetic translation is notoriously unreliable. Bioavailability, half-life, and tissue distribution in humans remain uncharacterized in peer-reviewed literature. The "300 mcg standard" is a clinical convention, not an evidence-based protocol.
What did they get wrong (or right)?
Credit where it's due: 300 mcg sub-Q once daily is the most commonly cited starting point in compounding pharmacy guidance and among clinicians who prescribe peptides off-label. It is not invented. It reflects a rough consensus that has emerged from clinical practice rather than controlled trials, and calling it a "standard" is a reasonable description of what practitioners actually do.
What's missing is more important than what's wrong. There is no acknowledgment that this dosing has no clinical trial backing in humans. There is no discussion of route selection rationale. Oral BPC-157 has been studied in some animal models (Sikiric et al., 2014, Journal of Physiology-Paris) and may have different absorption characteristics. Sub-Q is not automatically superior for this peptide. And doubling the dose, mentioned casually, doubles the unknowns on a compound with no established human safety profile at any dose.
What should you actually know?
BPC-157 is not FDA-approved. It was removed from the FDA's bulk substances list for compounding in 2022, meaning licensed compounding pharmacies in the US face significant restrictions on producing it. Any clinic offering it today is operating in a legally complicated space, regardless of how a clinician frames the dosing.
The honest summary is this: BPC-157 has a compelling animal research record for tissue healing and pain modulation, plausibly acting through nitric oxide pathways and growth hormone receptor interactions (Chang et al., 2011, Regulatory Peptides). Human data is essentially anecdotal and case-report level. The 300 mcg sub-Q figure is a practice convention, not a validated dose. Patients hearing this number on TikTok should not self-administer based on it, and they should ask any prescribing clinician direct questions about the legal status of what they are being prescribed.